review guid miss repeat
anoth disappoint quarter
sale growth miss conserv guid
sale street/bofaml estimate constant
currenc cc growth vs guid estimate better gross margin drove
adj ep in-lin first look detail overview
shortfal saw challeng industri appli strength pharma
despit easier comp saw mix perform across wat key end market
pharma impact soft europ us weak demand
instrument small molecul applic us declin flat industri growth
attribut linger food safeti headwind china partli off-set strength
materi us europ lag academ government weak
america china strong biomed demand europ china
continu lag continu weak food well macro uncertainti
outlook reduc question linger
cut already-twice-reduc sale guid cc growth vs prior
start lower adj ep vs prior
midpoint expect improv despit extra sell day new product
launch bioaccord cyclic im time issu end call also
start shift focu onto outlook stabil end-market
shipment new product well easi comp could drive reacceler next year
increment question underli strength portfolio given
pervas weak throughout ytd reiter under-perform rate
lower estim cut po
lower sale estim well adj
ep estim lower po po still
base ev/ebitda estimate discount peer
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
condit given gradual
deceler lc product cycl share shift
market expect continu soft
perform believ dynam take
time play
po base ev/ebitda estim slight discount
compani lst peer group support dcf analysi assum wacc
termin growth rate think discount justifi given end market
slow china tariff/trad war escal slower expect capit
deploy weaker global economi share loss competitor failur new
product deliv slowdown pharma biotech spend downsid risk
price object
upsid risk po faster expect capit deploy faster
expect uptak new product acquisit compani
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
